Pierre-Olivier Couraud

TL;DR: This review will focus on the implication of brain endothelial tight junctions in BBB architecture and physiology, will discuss the consequences of BBB dysfunction in these CNS diseases and will present some therapeutic strategies for drug delivery to the brain across the BBB.

TL;DR: The suitability of this brain microvascular endothelial cell line hCMEC/D3 as a human BBB model for pathogenic and drug transport studies is reviewed and critically considers its advantages and limitations.

TL;DR: Current understanding of the structure and functional regulation of endothelial TJs at the BBB is summarized, pointing to a correlation between BBB dysfunction, alteration of TJ complexes and progression of a variety of CNS diseases, such as stroke, multiple sclerosis and brain tumors, as well as neurodegenerative diseases like Parkinson's and Alzheimer’s diseases.

TL;DR: The extensive investigation of gene and protein patterns of transporters and metabolizing enzymes provides new molecular information for understanding drug entry and metabolism in the human blood-brain barrier.

TL;DR: This method of RBEC purification will allow the production of in vitro models of the rat blood–brain barrier for cellular and molecular biology studies as well as pharmacological investigations.